智通财经APP讯，科济药业-B(02171)发布截至2025年12月31日止年度业绩，收益1.26亿元(人民币，下同)，同比增长218.7%;母公司拥有人应占亏损9786.1万元，同比收窄87.7%;每股基本亏损0.18元。
截至2025年12月31日止年度，集团的收益主要来自赛恺泽® (自体BCMA CAR-T细胞产品)，其中赛恺泽®的主要收益乃以出厂价格而非终端市场价进行计算的。集团的收益于完成产品的出厂交付后确认。由于CAR-T生产存在必需的时间周期，从华东医药获得的订单数量与出厂交付的数量存在差异。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.